Jun-pyo Myong

Dr. Jun-pyo Myong

Department of Occupational and Environmental Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2011 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SKSu-jin Kim
Su-jin Kim
KLKyu Eun Lee
Kyu Eun Lee
JMJun-pyo Myong
Jun-pyo Myong
JPJeong‐Hwan Park
Jeong‐Hwan Park
YJYoon Kyung Jeon
Yoon Kyung Jeon
YYYeo-Kyu Youn
Yeo-Kyu Youn

1 March 2019 in JACC
Verified
Journal Article
Closed access
JKJu Youn Kim
Ju Youn Kim
SKSung-Hwan Kim
Sung-Hwan Kim
JMJun-pyo Myong
Jun-pyo Myong
YKYoo Ri Kim
Yoo Ri Kim
TKTae-Seok Kim
Tae-Seok Kim
TRTai-Ho Rho
Tai-Ho Rho

18 July 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
Osung KwonOsung Kwon
Osung Kwon
JMJun-pyo Myong
Jun-pyo Myong
YLYun-Hee Lee
Yun-Hee Lee
YCYeon‐Jik Choi
Yeon‐Jik Choi
JYJeong Eun Yi
Jeong Eun Yi
JLJungmin Lee
Jungmin Lee
Background: Whether the early use of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have cardioprotective effects following acute myocardial infarction is unknown. Thus, we aimed to evaluate the association between the early initiation of SGLT2 inhibitors and cardiac event rates in patients with diabetes with acute myocardial infarction undergoing percutaneous coronary intervention. Methods and Results: Based on the National Health Insurance claims data in South Korea, patients who received percutaneous coronary intervention for acute myocardial infarction between 2014 and 2018 were analyzed. Patients given SGLT2 inhibitors or other glucose‐lowering drugs were matched based on a propensity score. The primary end point was a composite of all‐cause mortality and hospitalizations for heart failure. Major adverse cardiac events (a composite of all‐cause death, nonfatal myocardial infarction, and ischemic stroke) were compared as the secondary end point. After 1:2 propensity score matching, the SGLT2 inhibitors group (938 patients) and the no use of SGLT2 inhibitors group (1876 patients) were compared. During a median follow‐up of 2.1 years, the early use of SGLT2 inhibitors was associated with lower risks of both the primary end point (9.8% versus 13.9%; adjusted hazard ratio [HR], 0.68 [95% CI, 0.54–0.87]; P =0.002) and secondary end point (9.1% versus 11.6%; adjusted HR, 0.77 [95% CI, 0.60–0.99]; P =0.04). All‐cause mortality and hospitalizations for heart failure were also significantly lower in early users of SGLT2 inhibitors. Conclusions: The early use of SGLT2 inhibitors in patients with diabetes treated with percutaneous coronary intervention for acute myocardial infarction was associated with a significantly lower risk of cardiovascular events, including all‐cause mortality, hospitalizations for heart failure, and major adverse cardiac events.

3 April 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
HCHa Kyun Chang
Ha Kyun Chang
JMJun-pyo Myong
Jun-pyo Myong
SBSeung Won Byun
Seung Won Byun
SLSung-Jong Lee
Sung-Jong Lee
YLYong Seok Lee
Yong Seok Lee
TPTae Chul Park
Tae Chul Park
Objectives Despite the possibility of early detection of cervical cancer, participation in screening programmes among young Koreans is low. We sought to identify associations between risk factors and participation in screening for cervical cancer among young Koreans. Design Nationwide cross-sectional study. Setting Republic of Korea. Participants 3734. Main outcome measures The Korea National Health and Nutrition Examination Survey (KNHANES V: 2010–2012) was used to evaluate factors associated with attendance for cervical cancer screening among women aged 15–39. After excluding those who were previously diagnosed with cervical cancer and those with incomplete responses to questionnaires, a total of 3734 subjects were eligible. Multi-dimensional covariates as potential predictors of cervical cancer screening were adjusted in multiple logistic regression analysis. Results The participation rate for cervical cancer screening was 46% among women aged 40 or younger. The logistic analyses showed that age, education, total household income, smoking and job status among women aged 15–39 were associated with participation in cervical cancer screening (p<0.05). After age stratification, the associated factors differed by age groups. Moreover, a dose–response between participation in cervical cancer screening and high total household income in the 30–39 age group was seen. Conclusions Predictive factors differed among young women (aged 15–29 vs 30–39). Thus, age-specific tailored interventions and policies are needed to increase the participation rate in screening for cervical cancer.

11 February 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SKSu-Jin Kim
Su-Jin Kim
SPSeog Yun Park
Seog Yun Park
YLYou Jin Lee
You Jin Lee
ELEun Kyung Lee
Eun Kyung Lee
SKSeok-Ki Kim
Seok-Ki Kim
KCKi-Wook Chung
Ki-Wook Chung